Pfizer
After Pfizer’s coronavirus boom, CEO in crosshairs over sales slump
It’s a sharp turn in fortune for Albert Bourla, who oversaw development and mass production of the novel RNA vaccine that helped get the pandemic under control and put the global economy back on track.
- by Daniel Gilbert
Latest
All rise for the incredible true story of Viagra’s first trials
In 1994, a group of Welshmen took part in a study for Viagra. But the little blue diamond was no magic pill.
- by Michael Lallo
Pfizer’s $14 billion COVID sales warning sparks investor relief
The past few days have been a reckoning for Pfizer, the pharma giant that gained most from the pandemic and has seen the biggest blow from its decline as demand for COVID shots and pills declined.
- by Nacha Cattan
COVID broke our pandemic rule book. What should be in our next plan?
We can’t predict when the next pandemic will come, but there are things we can learn from the last one.
- by Aisha Dow
Four-fifths of Australian adults have failed to get a bivalent booster. Here’s why that is a problem
A new variant of COVID-19 is on the rise, and the bivalent booster offers better protection from it.
- by Angus Dalton
Health officials warn of new, highly mutated COVID strain
Not much is known about BA.2.86, which was first spotted by virus trackers earlier this week and has already been detected in four countries.
- by Madison Muller
Fresh COVID-19 booster shot approved as 10m doses of new vaccine due to arrive
All adult Australians who have not had a COVID-19 infection or vaccination in the last six months can get an extra booster shot later this month.
- by Natassia Chrysanthos
Pfizer loses $57 billion in value as COVID bonanza wanes
Shares of Pfizer suffered a double-digit monthly decline as investors anticipate a troubled path ahead for the pharma giant, which expects sales of its COVID vaccine to slump 64 per cent this year.
- by Nacha Cattan and Bre Bradham
‘We can’t even protect ourselves’: Beijing hospital chaos as cases surge
“Too many patients who indeed need treatment have flooded in,” one nurse said in Beijing. “We feel helpless.”
- by Eryk Bagshaw
Exclusive
Science
mRNA giant wants changes to vaccine regulations to speed up new jabs
BioNTech is one of the world’s two leading mRNA companies, and it has just announced it will open a research and development hub in Melbourne.
- by Liam Mannix
Australia facing mRNA vaccine shortfall in global race for latest jabs
Australia risks being at the back of the global queue for variant-specific COVID-19 vaccines, with the government yet to strike a deal with Moderna for supply next year.
- by Dana Daniel
Original URL: https://www.brisbanetimes.com.au/topic/pfizer-inc-1nph